Project: A phase 2 and 3 clinical trial program to assess safety, efficacy and transmission blocking properties of the new anti-Malarial KAF156 combined with a new formulation of lumefantrine in children and adults with uncomplicated Plasmodium sp. Malaria in West and Central Africa

Acronym WANECAM 2 (Reference Number: RIA2017T-2018)
Duration 01/03/2019 - 29/02/2024
Project Topic Despite major progress in the past decade malaria remains a major public health problem in sub-Saharan Africa, where 90% of the 216 million new cases and 91% of the 445 000 deaths from malaria in 2016 occurred. West and Central Africa account for nearly 2/3 of the morbidity and mortality currently attributable to Plasmodium falciparum malaria. Artemisinin-based combination therapies (ACT) are a cornerstone of our strategy for controlling and eventually eliminating malaria. However, reduced responsiveness/resistance to artemisinin derivatives and to ACTs is now an increasing problem in South-East Asia. In Africa, although artemisinins remain efficacious, failure of ACTs due to resistance to partner drugs is also of concern. Therefore, it is of utmost importance to develop new antimalarial drugs that are from novel chemical classes and thus can break resistance. KAF156, an imidazolepiperazine, is one of the leading candidates in the antimalarial drug development pipeline. It is a novel antimalarial drug being developed by Novartis with scientific and financial support from MMV (in collaboration with the Bill & Melinda Gates Foundation). Its structure and mode of action are different from currently marketed antimalarial drugs and other antimalarial drug candidates. The Solid Dispersion Formulation of lumefantrine (LUM-SDF) is an improved form of lumefantrine that is less susceptible to food effects and can be used once daily instead of twice daily. The new combination of KAF156 with LUM-SDF is expected to be fast acting, fully curative, improve patient adherence and can potentially reduce malaria transmission. Building on our successful experience of effectively contributing to line extension and label variation of Pyramax during EDCTP1 through our WANECAM I consortium (, here we propose to substantially advance the clinical development of KAF156. We will also build a new clinical research team in Niger, a grossly underrepresented country in the African research landscape, and improve targeted capacities and infrastructure in all teams involved. We will train young African and European scientists through short courses, MSc and PhD training. All of these activities will be undertaken in the context of networking, team-building, leadership development and community engagement schemes that will involve intra-European, European-African and intra-African collaborative activities. By the end of the five years of this project, we intend to contribute to the registration of KAF156/LUM-SDF through stringent regulatory health authorities, increase biomedical research capacity in the Consortium and effectively promote networking among our respective teams.
Network EDCTP2
Call Treatment innovations for poverty-related diseases

Project partner

Number Name Role Country
1 Université des Sciences, des Techniques et des Technologies de Bamako Coordinator Mali
4 Academisch Medisch Centrum bij de Universiteit van Amsterdam Partner Netherlands
6 Centre de Recherches Médicales de Lambaréné Partner Gabon
9 Eberhard Karls Universität Tübingen Partner Germany
12 Groupe de Recherche Action en Santé sarl. Partner Burkina Faso
15 Institut des Sciences et Techniques Partner Burkina Faso
18 Karolinska Institutet Partner Sweden
20 London School of Hygiene and Tropical Medicine Partner United Kingdom
22 Medicines for Malaria Venture Partner Switzerland
23 Novartis Pharma AG Partner Switzerland
24 Universite Abdou Moumouni de Niamey Partner Niger
27 Universite Claude Bernard Lyon 1 Partner France